Scientific Program Day Two

Thursday | June 27, 2024

과학 프로그램 2 일 차


カンファレンス 2日目

7:00 am Coffee & Check-In

7:50 am Chair’s Opening Remarks

  • Nitin Damle Executive Vice President and Chief Innovation Officer, Sun Pharma

Identifying Novel Targets & Their Benefits to Diversify ADC Programs & Design a More Accurate ADC

8:00 am Unmet Needs in ADCs for Gastrointestinal Cancer: East-West Differences & Novel Target Strategies Beyond HER2 & TROP2


  • Addressing the unmet needs of ADCs in gastrointestinal cancers
  • Discussing the regional differences in the need for an ADC for gastrointestinal cancers
  • Going beyond HER2 and TROP2: Novel targets for ADCs in gastrointestinal cancers

8:30 am Developing a Precise ADC for Novel Targets to Take Your ADC From Bench to Bedside


  • Exploring target discovery for ADCs
  • Understanding pre-clinical and clinical translation
  • Developing the best-in-class ADC for precision oncology

9:00 am SGN-B6A: A Vedotin Antibody-Drug Conjugate that Targets Integrin Beta-6 & Shows Clinical Efficacy in Multiple Solid Tumor Indications


  • Explore how SGN-B6A is an investigational, first-in-class ADC, which shows high specificity towards integrin beta-6
  • Overview of SGN-B6A preclinical and clinical safety and efficacy data
  • Discuss the rationale for clinical combination between SGN-B6A and CPIs 

9:30 am Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP® Technology


Session Hosted by: Ajinomoto Biopharma Services

  • AJICAP®️ Conjugation: Examining how site-specific technologies are being employed in many of the next-generation ADCs due to the enhancement of clinically relevant biological properties observed in various preclinical studies
  • AJICAP®️ Linker: Demonstrating a novel hydrophilic linker technology that enables the versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
  • Showcasing Bispecific and Trispecific antibodies produced by fully-chemical conjugation technology

10:00 am Morning Networking Break

11:00 am NN3201, a Novel C-Kit Targeting ADC, Exhibits Robust Preclinical AntiTumor Efficacy in SCLC & GIST Models


  • Navigating the effects of NN3201 in small cell lung cancer
  • Exploring a novel C-Kit targeting ADC
  • Showing anti-tumor efficacy in SCLC and GIST models

Innovating Novel Linker & Payload Technologies to Increase Stability, Efficiency & Patient Treatability

11:30 am Delivery of BET Protein Degrader to Pancreatic Cancer & Their Microenvironment Via CEACAM6-Targeted Antibody–Drug Conjugate


  • Analyzing Antibody protein degrader conjugate
  • Understanding pancreatic cancer and its effects
  • Reviewing a novel payload, BET protein degrader

12:00 pm From Concept to Market: Accelerating ADC Development With WuXi XDC’s Fully Integrated Discovery & CMC Platforms


Session Hoested by: WuXi Biologics

  • Showcasing the one-stop integrated discovery service platform focusing on bioconjugate lead selection that includes mAb/protein generation, payload linker synthesis, bioconjugate preparation, in vitro and in vivo characterization
  • Demonstrating fully integrated ADC CMC development and manufacturing with industry leading DNA to IND timeline of 15 months; mAb/payload-linker/conjugation DS & DP all by in-house team and facilities
  • Sharing vast ADC experience with 250+ discovery projects, 75+ CMC projects, 27+ INDs

12:30 pm
Networking Lunch

1:00 pm A Flourishing ADC space

  • Jia He Researcher, Beacon Targeted Therapies


  • Review of the current ADC landscape, both clinical and preclinical
  • Deep dive into the characteristics of ADCs in each stage of development
  • Analyze trends on the recent flurry of ADC deals

1:30 pm Exploring Next-Generation ADC Development From Payload & Linker Perspective to Drive ADC Performance & Innovation


  • Explore a new Topoisomerase 1 inhibitor
  • Discuss a new linker system for ADC
  • Review how it had better performance than Enhertu

2:00 pm Analyzing the Advantages of Protein Homeostasis by Dual Precision Approach


  • Discover the development of a novel, catalytic payload class
  • Explore diversity of degrader SAR while also enabling conjugation
  • Improve potency and selectivity of delivery to target cells

2:30 pm Afternoon Networking Break

Maximizing Therapeutic Window to Increase Efficacy & Reduce Off-Target Toxicity of Your ADC

2:40 pm End of Conference

3:00 pm PEG-Based Bispecific ADC: Better Tumor Penetration, Wider Therapeutic Window


  • Assessing how it provides better tumor penetration
  • Discussing how there were not any Fc related toxicities
  • Exploring how it has a wider therapeutic window

3:30 pm Effective PK/PD Translational Strategies to Enable a Successful Early Clinical Development

  • Mike Liao Pharmacology Team Lead, Global Clinical Pharmacology Lead & BD Diligence Evaluator, Genentech


  • Defining the translational PK/PD considerations for ADC FIH starting dose prediction
  • Integrating nonclinical knowledge through computational modeling and simulations to inform Phase I design dose escalations.
  • Exploring translational PK/PD data to support model-informed clinical safety mitigation strategy, drug-drug interaction risks

4:00 pm Understanding How Therapeutic Window Differs From Patient to Patient to Incorporate Individual Therapy & Find the Maximum Tolerable Dose

  • Amy Han Exec Dir of R&D chem, Regeneron Pharmaceuticals


  • Navigating varying patient immune responses
  • Using differing immune responses to individualize therapy
  • Evaluating the benefits of individualized therapy

4:30 pm Chair’s Closing Remarks

  • Nitin Damle Executive Vice President and Chief Innovation Officer, Sun Pharma